These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33053478)

  • 1. Lysins breaking down the walls of Gram-negative bacteria, no longer a no-go.
    Gutiérrez D; Briers Y
    Curr Opin Biotechnol; 2021 Apr; 68():15-22. PubMed ID: 33053478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering a Lysin with Intrinsic Antibacterial Activity (LysMK34) by Cecropin A Fusion Enhances Its Antibacterial Properties against Acinetobacter baumannii.
    Abdelkader K; Gutiérrez D; Tamés-Caunedo H; Ruas-Madiedo P; Safaan A; Khairalla AS; Gaber Y; Dishisha T; Briers Y
    Appl Environ Microbiol; 2022 Jan; 88(1):e0151521. PubMed ID: 34669452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacteriophages that infect Gram-negative bacteria as source of signal-arrest-release motif lysins.
    Gontijo MTP; Vidigal PMP; Lopez MES; Brocchi M
    Res Microbiol; 2021 Mar; 172(2):103794. PubMed ID: 33347948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteriophage-derived endolysins to target gram-negative bacteria.
    Lai WCB; Chen X; Ho MKY; Xia J; Leung SSY
    Int J Pharm; 2020 Nov; 589():119833. PubMed ID: 32877733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using a bacteriocin structure to engineer a phage lysin that targets Yersinia pestis.
    Lukacik P; Barnard TJ; Buchanan SK
    Biochem Soc Trans; 2012 Dec; 40(6):1503-6. PubMed ID: 23176506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of the direct antimicrobial activity of Lysep3 against Escherichia coli by inserting cationic peptides into its C terminus.
    Ma Q; Guo Z; Gao C; Zhu R; Wang S; Yu L; Qin W; Xia X; Gu J; Yan G; Lei L
    Antonie Van Leeuwenhoek; 2017 Mar; 110(3):347-355. PubMed ID: 27943012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysocins: Bioengineered Antimicrobials That Deliver Lysins across the Outer Membrane of Gram-Negative Bacteria.
    Heselpoth RD; Euler CW; Schuch R; Fischetti VA
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation of Phage Lysins That Effectively Kill Pseudomonas aeruginosa in Mouse Models of Lung and Skin Infection.
    Raz A; Serrano A; Hernandez A; Euler CW; Fischetti VA
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phages and engineered lysins as an effective tool to combat Gram-negative foodborne pathogens.
    Kocot AM; Briers Y; Plotka M
    Compr Rev Food Sci Food Saf; 2023 May; 22(3):2235-2266. PubMed ID: 37009835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant bacteriophage lysins as antibacterials.
    Fenton M; Ross P; McAuliffe O; O'Mahony J; Coffey A
    Bioeng Bugs; 2010; 1(1):9-16. PubMed ID: 21327123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal Delivery of Newly Identified Prophage Lysins in a
    Morais D; Tanoeiro L; Marques AT; Gonçalves T; Duarte A; Matos APA; Vital JS; Cruz MEM; Carvalheiro MC; Anes E; Vítor JMB; Gaspar MM; Vale FF
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077542
    [No Abstract]   [Full Text] [Related]  

  • 12. Advanced engineering of third-generation lysins and formulation strategies for clinical applications.
    De Maesschalck V; Gutiérrez D; Paeshuyse J; Lavigne R; Briers Y
    Crit Rev Microbiol; 2020 Sep; 46(5):548-564. PubMed ID: 32886565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria.
    Briers Y; Lavigne R
    Future Microbiol; 2015; 10(3):377-90. PubMed ID: 25812461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond antibiotics: phage-encoded lysins against Gram-negative pathogens.
    Shah S; Das R; Chavan B; Bajpai U; Hanif S; Ahmed S
    Front Microbiol; 2023; 14():1170418. PubMed ID: 37789862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct mode of action of a highly stable, engineered phage lysin killing Gram-negative bacteria.
    Gerstmans H; Duyvejonck L; Vázquez R; Staes I; Borloo J; Abdelkader K; Leroy J; Cremelie E; Gutiérrez D; Tamés-Caunedo H; Ruas-Madiedo P; Rodríguez A; Aertsen A; Lammertyn J; Lavigne R; Briers Y
    Microbiol Spectr; 2023 Dec; 11(6):e0181323. PubMed ID: 37971248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials.
    Vázquez R; García E; García P
    Front Immunol; 2018; 9():2252. PubMed ID: 30459750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of net charge on catalytic domain and influence of cell wall binding domain on bactericidal activity, specificity, and host range of phage lysins.
    Low LY; Yang C; Perego M; Osterman A; Liddington R
    J Biol Chem; 2011 Sep; 286(39):34391-403. PubMed ID: 21816821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural engineering of a phage lysin that targets gram-negative pathogens.
    Lukacik P; Barnard TJ; Keller PW; Chaturvedi KS; Seddiki N; Fairman JW; Noinaj N; Kirby TL; Henderson JP; Steven AC; Hinnebusch BJ; Buchanan SK
    Proc Natl Acad Sci U S A; 2012 Jun; 109(25):9857-62. PubMed ID: 22679291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacteriophage lysins as effective antibacterials.
    Fischetti VA
    Curr Opin Microbiol; 2008 Oct; 11(5):393-400. PubMed ID: 18824123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of cationic peptide chimeric lysins based on phage lysin Lysqdvp001 and their antibacterial effects against Vibrio parahaemolyticus: A preliminary study.
    Ning H; Cong Y; Lin H; Wang J
    Int J Food Microbiol; 2021 Nov; 358():109396. PubMed ID: 34560361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.